Beam Therapeutics Inc. Non Peo Neo Avg Total Comp Amt
Beam Therapeutics Inc. (BEAM) reported Non Peo Neo Avg Total Comp Amt of $2.31 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-17.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-17
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $2.31M DEF 14A · filed 2026-04-17 |
| 2024-12-31 | $3.23M DEF 14A · filed 2026-04-17 |
| 2023-12-31 | $2.54M DEF 14A · filed 2026-04-17 |
| 2022-12-31 | $3.06M DEF 14A · filed 2026-04-17 |
| 2021-12-31 | $4.74M DEF 14A · filed 2026-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |